Clinical Trials Logo

Clinical Trial Summary

- To find out the gap between real-world clinical practice and guideline recommendations in initial management of DTC patients - To observe the characteristics of patients who achieved and did not achieve TSH target value after five year follow-up - To assess response to initial therapy in patients who undergo total or neartotal thyroidectomy and RAI remnant ablation after five year follow-up (according to an modified dynamic risk stratification system) - To observe the recurrence status after five year follow-up

Clinical Trial Description

The DTCC 2nd will follow DTCC 1st and observe the long-term efficacy of initial management including surgery treatment, 131I therapy and TSH suppression therapy. It will involve nine hospitals which have participated in the first stage, and continually to observe the DTC patients who were recruited. The patients with more than 5 years long-term follow-up from the date of signing the informed consent form (ICF) in DTCC 1st to signing ICF in DTCC 2nd will be collected data retrospectively. For those follow-up less than 5 years, in addition to the retrospective data collection, one prospective visit will be conducted. Primary endpoint(s) 1.Five-year accumulated recurrence rate Secondary endpoint(s) 1. Disease-free survival (DFS) 2. Overall survival (OS) 3. Response to therapy 4. Re-operation rate 5. Time weighted TSH level (TW-TSH) 6. Adverse events related to L-T4 therapy (ADRs) 7. Median follow-up years ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04857086
Study type Observational
Source Huazhong University of Science and Technology
Contact Jie Ming, M.D.
Phone 8610 02785351622
Email [email protected]
Status Recruiting
Start date December 30, 2020
Completion date March 28, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02870569 - Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer Phase 2
Active, not recruiting NCT01876784 - Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Phase 3
Recruiting NCT03690388 - A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Phase 3
Recruiting NCT02638077 - Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China N/A
Recruiting NCT01700699 - Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT04563780 - The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
Completed NCT03191643 - PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer N/A
Completed NCT02278198 - Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123 Phase 1
Active, not recruiting NCT01263951 - Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone Phase 2
Completed NCT00295763 - A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Phase 3
Not yet recruiting NCT04858867 - Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET) N/A
Recruiting NCT04391244 - Investigating National Solutions for Personalised Iodine-131 Radiation Exposure
Recruiting NCT04137185 - Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients Phase 1/Phase 2
Active, not recruiting NCT02586337 - Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) Phase 2/Phase 3
Not yet recruiting NCT03416686 - Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy N/A
Completed NCT02304757 - 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Decreased Bone Mineral Density N/A
Recruiting NCT03986437 - A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.
Enrolling by invitation NCT03794375 - Primary Care Transfer for Thyroid Cancer Patients N/A